This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Yourgene Health Past Earnings Performance

Past criteria checks 0/6

Yourgene Health's earnings have been declining at an average annual rate of -3.8%, while the Medical Equipment industry saw earnings growing at 9.3% annually. Revenues have been growing at an average rate of 37% per year.

Key information

-3.8%

Earnings growth rate

20.7%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate37.0%
Return on equity-31.4%
Net Margin-27.6%
Last Earnings Update30 Sep 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Yourgene Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:VILG.F Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2230-8170
30 Jun 2234-5180
31 Mar 2238-2180
31 Dec 2133-6180
30 Sep 2128-10170
30 Jun 2123-11160
31 Mar 2118-12140
31 Dec 2018-8130
30 Sep 2017-4120
30 Jun 2017-3110
31 Mar 2017-2110
31 Dec 1915190
30 Sep 1913580
30 Jun 1911480
31 Mar 199380
31 Dec 188-290
30 Sep 187-890
30 Jun 187-990
31 Mar 186-990
31 Dec 175-990
30 Sep 174-990
30 Jun 174-990
31 Mar 173-880
31 Dec 163-1080
30 Sep 163-1180
30 Jun 163-1270
31 Mar 162-1270
30 Sep 151-750
31 Mar 150-740
28 Feb 140-220

Quality Earnings: VILG.F is currently unprofitable.

Growing Profit Margin: VILG.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VILG.F is unprofitable, and losses have increased over the past 5 years at a rate of 3.8% per year.

Accelerating Growth: Unable to compare VILG.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VILG.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (5%).


Return on Equity

High ROE: VILG.F has a negative Return on Equity (-31.41%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/05 10:36
End of Day Share Price 2023/06/09 00:00
Earnings2022/09/30
Annual Earnings2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yourgene Health Plc is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCavendish
Mark BrewerCavendish
Martin HallHardman & Co.